Advertisement
UK markets closed
  • FTSE 100

    8,275.38
    +44.33 (+0.54%)
     
  • FTSE 250

    20,730.12
    +59.25 (+0.29%)
     
  • AIM

    805.79
    +3.10 (+0.39%)
     
  • GBP/EUR

    1.1742
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2738
    +0.0006 (+0.05%)
     
  • Bitcoin GBP

    53,171.16
    +238.47 (+0.45%)
     
  • CMC Crypto 200

    1,426.77
    -1.79 (-0.13%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • DOW

    38,686.32
    +574.84 (+1.51%)
     
  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     
  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     
  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     
  • HANG SENG

    18,079.61
    -150.58 (-0.83%)
     
  • DAX

    18,497.94
    +1.15 (+0.01%)
     
  • CAC 40

    7,992.87
    +14.36 (+0.18%)
     

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S
Novo Nordisk A/S

Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.2 billion in the period from 7 May 2024 to 5 August 2024.

Since the announcement 6 May 2024, the following transactions have been made:

 

Number of B shares

Average purchase price

Transaction value, DKK

7 May 2024

41,500

871.78

36,178,694

8 May 2024

41,000

889.00

36,449,139

13 May 2024

40,500

903.66

36,598,358

14 May 2024

40,000

917.73

36,709,080

15 May 2024

40,000

917.59

36,703,733

16 May 2024

39,000

911.68

35,555,455

Accumulated under the programme

242,000

 

218,194,459

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

ADVERTISEMENT

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 63,694 B shares in the period from 07 May 2024 to 16 May 2024. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 10,341,814 B shares of DKK 0.10 as treasury shares, corresponding to 0.2% of the share capital. The total amount of A and B shares in the company is 4,446,500,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 16 May 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 8,976,250 B shares at an average share price of DKK 862.94 per B share equal to a transaction value of DKK 7,745,929,232.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
        

Contact for further information.

Media:

 

Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com

Investors:

 

Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com

Ida Melvold Gjøsund
+45 3077 5649 idmg@novonordisk.com

 

Company announcement No 43 / 2024

Attachments